Loading...
•
Jun 30, 2021
Bio-Rad Q2 2021 Earnings Report
Bio-Rad's financial performance was strong, driven by recovery in end markets and adaptation to COVID-19 constraints.
Key Takeaways
Bio-Rad Laboratories reported a strong second quarter in 2021, with net sales increasing by 33.4% to $715.9 million compared to the same period in 2020. The company's Life Science and Clinical Diagnostics segments both performed well, and the company has updated its full-year guidance to reflect this performance.
Second-quarter net sales increased by 33.4% to $715.9 million compared to Q2 2020.
Life Science segment net sales increased by 32.6% to $334.2 million compared to the same quarter last year.
Clinical Diagnostics segment sales increased by 34.3% to $380.2 million compared to the same period last year.
The company anticipates non-GAAP currency-neutral revenue growth between 10.0 to 10.5 percent for the full year 2021.
Revenue by Segment
Forward Guidance
The company has updated its guidance and now anticipates non-GAAP currency-neutral revenue growth between 10.0 to 10.5 percent and an estimated non-GAAP operating margin of approximately 19.0 percent for the full year 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...